ストックスクリーナーアプリを入手
5.79
1.22%
0.07
アフターアワーズ：
5.74
-0.05
-0.86%
前日終値:
$5.72
開ける：
$5.78
24時間の取引高:
4.14M
Relative Volume:
0.57
時価総額：
$1.99B
収益：
-
当期純損益:
$-75.80M
株価収益率:
-16.54
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
+3.02%
1か月 パフォーマンス:
-10.37%
6か月 パフォーマンス:
+149.57%
1年 パフォーマンス:
+153.95%
1日の値動き範囲:
$5.515
$5.885
1週間の範囲:
$5.31
$6.15
52週間の値動き範囲:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.79 | 1.96B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-19 | 開始されました | B. Riley Securities | Buy |
| 2025-09-30 | 開始されました | Jefferies | Buy |
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Forecasting The Future: 9 Analyst Projections For Nuvation Bio - Benzinga
Nuvation Bio's (NUVB) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma - BioSpace
Nuvation Bio expands SIGMA trial to phase 3 for IDH1-mutant glioma - Investing.com Canada
Nuvation Bio announces pivotal global phase 3 Sigma trial (G203) for Safusidenib in IDH1-mutant glioma - marketscreener.com
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial for Safusidenib in IDH1-Mutant Glioma - Investing News Network
S P Trends: Is Nuvation Bio Inc stock undervalued right nowPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring 111.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Nuvation Bio stock maintains Buy rating at B.Riley on Ibtrozi sales momentum - Investing.com Nigeria
Analyst Endorsements Of Ibtrozi Uptake Could Be A Game Changer For Nuvation Bio (NUVB) - Sahm
Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy (NYSE:NUVB) - Seeking Alpha
Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential - Yahoo Finance
Turist Financial Remains a Buy on Nuvation Bio (NUVB) - Finviz
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - Insider Monkey
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Nuvation Bio price target raised to $13 from $11 at Truist - Yahoo Finance
Truist Securities raises Nuvation Bio stock price target to $13 on Ibtrozi uptake - Investing.com Nigeria
Nuvation Bio Inc. (NUVB) price target lowered as IBTROZI sales meet expectations - MSN
Is Nuvation Bio Inc. stock undervalued right now2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - mfd.ru
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement - Sahm
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - 富途资讯
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvation Bio Inc. (NUVB) Stock Analysis: 97% Potential Upside with Promising Oncology Pipeline - DirectorsTalk Interviews
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2%Here's Why - MarketBeat
Why Nuvation Bio (NUVB) Is Down 8.2% After Expanding Global Taletrectinib Partnership With Eisai - simplywall.st
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Yahoo Finance
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
10 Stocks Under $10 with High Potential - Insider Monkey
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
A Look At Nuvation Bio’s Valuation After The Eisai Taletrectinib Collaboration Agreement - Sahm
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Nigeria
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study By Investing.com - Investing.com Australia
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):